Taipei Medical University1.0
  • 2020 Feb 21
  • TMU GLORIA International Symposium: Tumor Immunotherapy: Past Present & Future

International Symposium on Cancer Immunotherapy Attracts Professionals from Industry, Research, and Medicine

Taipei Medical University GLORIA and GLORIA member Lifenergy Biotech Corp. held an international academic seminar Tumor Immunotherapy: Past, Present, and Future on November 27, 2019. Dr. Jun Yan, the Endowed Chair of the Division of Immunotherapy, Department of Surgery, University of Louisville, USA, was invited to share recent trends in tumor immunotherapy.
Cancer is the leading cause of death among people in the country, and the medical community continues to seek solutions. In recent years, immunotherapy has been the most popular, and quite a lot of new drug research progress and clinical trial data have been published. Professor Yan has been working on cancer immunotherapy for more than 30 years. He has also received many important research sponsored by the National Institutes of Health (NIH).
Professor Yan shared the challenges and recent trends in cancer immunotherapy during the conference. Yan Jun pointed out that although immunotherapy can be called the latest wave of cancer therapy, it still faces a number of challenges, including the limited overall response rate and the lack of biomarkers that can predict the response of patients to treatment. (biomarker), tumors may appear drug resistance, and serious immune-related side effects may occur. He said that the latest concept of immunotherapy today is to focus on the "immune microenvironment" around cancer cells. Many scientists are also focusing on how to improve the efficacy of immunotherapy by regulating the immune microenvironment. In other words, "cold tumors" (infiltrated-excluded) with immune cell infiltration only in the periphery of the tumor are transformed into "infiltrated-inflamed" which is more sensitive to immunotherapy. "
Professor Yan has long been committed to the research of "yeast staphylococcal polysaccharide-beta glucan", and he pointed out that there have been many studies published confirming β-1,3 / 1,6 yeast dextran 1,6 gluco polysaccharides (WGP) has the effect of reversing the microenvironment of tumors, transforming M2 macrophages into M1 type, and has the function of regulating the immune system. It can be used as an "antibiotic" to help the immune system fight cancer.


Professor Yan shares the latest trends in cancer immunotherapy